Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01155583 | Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 45 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT02897830 | Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma(IFM2014-03) | terminated | Phase 2 | 46 | University Hospital, ToulouseOTHER | 1 | Nov 12, 2020 |
| clinicaltrials |
| NCT03033316 | A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma(AMETHYST) | terminated | Phase 1 / Phase 2 | 7 | Enceladus Pharmaceuticals BVINDUSTRY | 0 | Nov 6, 2020 | clinicaltrials |
| NCT00966693 | Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 77 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT03287804 | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma(APRIL) | terminated | Phase 1 / Phase 2 | 12 | Autolus LimitedINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT02477215 | Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 38 | Parameswaran HariOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02217163 | Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma | completed | Phase 2 | 30 | Singapore General HospitalOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT00821249 | A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 55 | PfizerINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02092922 | A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM) | completed | Phase 2 | 154 | PfizerINDUSTRY | 8 | Oct 19, 2020 | clinicaltrials |
| NCT02192775 | UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus | completed | Phase 2 | 2 | University of ArkansasOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02237261 | Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma(BPV) | completed | Phase 2 | 46 | University Hospital HeidelbergOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | terminated | Phase 2 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT00469209 | Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients | completed | Phase 1 / Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT00075621 | Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis | completed | Phase 2 | 62 | Boston Medical CenterOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT02952573 | Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement | terminated | Phase 2 | 20 | University Health Network, TorontoOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT01989325 | A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma | completed | Phase 2 | 77 | PfizerINDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT00309842 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | completed | Phase 2 | 213 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT01090921 | Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 50 | Boston VA Research Institute, Inc.OTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT00718419 | A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma | completed | Phase 2 | 56 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 3, 2020 | clinicaltrials |
| NCT00570180 | Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma | completed | Phase 2 | 36 | University Health Network, TorontoOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT01842308 | Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 50 | Mayo ClinicOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT01605032 | Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 19 | Albert Einstein College of MedicineOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01885897 | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | completed | Phase 1 / Phase 2 | 33 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT03669445 | Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma(IFM2018-01) | unknown | Phase 2 | 45 | University Hospital, ToulouseOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT04439305 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2020 | clinicaltrials |
| NCT02219178 | Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 42 | Cancer Trials IrelandNETWORK | 1 | Jul 17, 2020 | clinicaltrials |
| NCT01832727 | Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 65 | AmgenINDUSTRY | 2 | Jul 13, 2020 | clinicaltrials |
| NCT03003728 | 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Jul 10, 2020 | clinicaltrials |
| NCT01858558 | Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma | completed | Phase 2 | 102 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 29, 2020 | clinicaltrials |
| NCT00985907 | Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma(DMV) | terminated | Phase 1 / Phase 2 | 13 | University of California, San FranciscoOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT00903968 | Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 58 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03492138 | Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 5 | Ajai ChariOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT02003625 | Meloxicam vs Placebo for Mobilization | completed | Phase 2 | 31 | Massachusetts General HospitalOTHER | 1 | May 18, 2020 | clinicaltrials |
| NCT00303719 | Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | terminated | Phase 2 | 342 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT01237951 | High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma | completed | Phase 2 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02636010 | Pembrolizumab (MK-3475) in MM Patients With Residual Disease | completed | Phase 2 | 20 | PETHEMA FoundationOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT01660633 | Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation | completed | Phase 2 | 61 | Acrotech Biopharma Inc.INDUSTRY | 1 | Apr 21, 2020 | clinicaltrials |
| NCT01212952 | Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 50 | Mayo ClinicOTHER | 1 | Apr 17, 2020 | clinicaltrials |
| NCT01245673 | Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma | completed | Phase 2 | 28 | University of PennsylvaniaOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT04024384 | Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial(DARALLO) | withdrawn | Phase 2 | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT02902965 | Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 74 | Pharmacyclics Switzerland GmbHINDUSTRY | 6 | Mar 16, 2020 | clinicaltrials |
| NCT02756728 | A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma | terminated | Phase 1 / Phase 2 | 5 | BioInvent International ABINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01478581 | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 92 | Pharmacyclics LLC.INDUSTRY | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02168101 | Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma | completed | Phase 2 | 9 | SCRI Development Innovations, LLCOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT02928029 | Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 7 | BayerINDUSTRY | 3 | Feb 26, 2020 | clinicaltrials |
| NCT03385096 | Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01438177 | Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma | terminated | Phase 2 | 11 | NYU Langone HealthOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT03328936 | Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant | withdrawn | Phase 2 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 21, 2020 | clinicaltrials |
| NCT01049945 | Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 70 | Mayo ClinicOTHER | 1 | Feb 11, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Nov 16, 2020source: clinicaltrials